• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Letter to the editor: consideration on: 'What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?' by Reid I.R.

作者信息

Di Monaco Marco, Castiglioni Carlotta, Bardesono Francesca

机构信息

Osteoporosis Research Center, San Camillo Foundation, Turin, Italy.

出版信息

Expert Opin Drug Saf. 2023 Jan;22(1):103-104. doi: 10.1080/14740338.2023.2173737. Epub 2023 Jan 29.

DOI:10.1080/14740338.2023.2173737
PMID:36710441
Abstract
摘要

相似文献

1
Letter to the editor: consideration on: 'What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?' by Reid I.R.
Expert Opin Drug Saf. 2023 Jan;22(1):103-104. doi: 10.1080/14740338.2023.2173737. Epub 2023 Jan 29.
2
What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?接受罗莫索单抗治疗的骨质疏松症患者发生心血管事件的风险是什么？
Expert Opin Drug Saf. 2022 Dec;21(12):1441-1443. doi: 10.1080/14740338.2022.2160445. Epub 2022 Dec 27.
3
Romosozumab for the treatment of osteoporosis in women: Efficacy, safety, and cardiovascular risk.罗莫佐单抗治疗女性骨质疏松症：疗效、安全性和心血管风险。
Womens Health (Lond). 2022 Jan-Dec;18:17455057221125577. doi: 10.1177/17455057221125577.
4
Cardiovascular Safety and Sclerostin Inhibition.心血管安全性与硬骨素抑制
J Clin Endocrinol Metab. 2021 Jun 16;106(7):1845-1853. doi: 10.1210/clinem/dgab193.
5
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.罗莫佐单抗或阿仑膦酸钠用于预防骨质疏松症女性骨折。
N Engl J Med. 2017 Oct 12;377(15):1417-1427. doi: 10.1056/NEJMoa1708322. Epub 2017 Sep 11.
6
Explanations for the difference in rates of cardiovascular events in a trial of alendronate and romosozumab.阿仑膦酸钠和罗莫佐单抗试验中心血管事件发生率差异的解释。
Osteoporos Int. 2020 Jun;31(6):1019-1021. doi: 10.1007/s00198-020-05379-z. Epub 2020 Apr 4.
7
Amgen and UCB announce increased cardiovascular risk in patients receiving romosozumab, an anti-sclerotin antibody.
Rheumatology (Oxford). 2017 Aug 1;56(8):e21. doi: 10.1093/rheumatology/kex244.
8
Romosozumab: A Review in Postmenopausal Osteoporosis.罗莫佐单抗：用于绝经后骨质疏松症的研究综述。
Drugs Aging. 2020 Nov;37(11):845-855. doi: 10.1007/s40266-020-00793-8.
9
Romosozumab (Evenity) for postmenopausal osteoporosis.罗莫单抗（艾地骨化醇）用于绝经后骨质疏松症。
Med Lett Drugs Ther. 2019 Jun 3;61(1573):83-86.
10
[Sequential treatment of osteoporosis with anti-sclerostin.].[抗硬化蛋白序贯治疗骨质疏松症。]
Clin Calcium. 2019;29(3):363-369. doi: 10.20837/4201903363.